<DOC>
	<DOC>NCT02582658</DOC>
	<brief_summary>The study seeks to provide evidence of the effectiveness and obtain patient reported outcome (PRO) and work productivity data of the interferon-free ABBVIE REGIMEN +/- Ribavirin (RBV) in chronic hepatitis C virus infected participants in Austria.</brief_summary>
	<brief_title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Treatmentnaïve or experienced adult male or female patients with confirmed chronic hepatitis C, genotype 1 or 4, receiving combination therapy with the interferonfree ABBVIE REGIMEN ± Ribavirin (RBV) according to standard of care and in line with the current local label If RBV is coadministered with the ABBVIE REGIMEN, it has been prescribed in line with the current local label (with special attention to contraception requirements and contraindication during pregnancy) Patients must voluntarily sign and date a patient authorization to use and disclose his/her anonymized health data prior to inclusion into the study Patient must not be participating or intending to participate in a concurrent interventional therapeutic trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Paritaprevir</keyword>
	<keyword>Dasabuvir</keyword>
	<keyword>Ombitasvir</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>HCV</keyword>
</DOC>